Anvisa Approves First Inhaled Insulin in Brazil

The product can replace ultra-fast injectable insulin, generally used at mealtimes, but is not recommended for children under eighteen or patients with lung conditions.

By Xiu Ying, Contributing Reporter

RIO DE JANEIRO, BRAZIL - The National Health Surveillance Agency (Anvisa) authorized the marketing of the first inhalable insulin in the country. The decision granting registration of the product was approved last Thursday, May 30th, and published this Monday, June 3rd, in the Diário Oficial da União (Federal Gazette).

Named Afrezza, the new insulin is sold in powder form, in capsules with three different types of dosage. The diabetic patient needs to insert the capsule into the inhaler and draw in the powder for use.

The substance reaches the lungs and is absorbed into . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?